ES2174273T3 - Uso de heparina o heparan-sulfato en combinacion con quitosan para la prevencion o el tratamiento de infecciones causadas por virus herpes. - Google Patents

Uso de heparina o heparan-sulfato en combinacion con quitosan para la prevencion o el tratamiento de infecciones causadas por virus herpes.

Info

Publication number
ES2174273T3
ES2174273T3 ES97934838T ES97934838T ES2174273T3 ES 2174273 T3 ES2174273 T3 ES 2174273T3 ES 97934838 T ES97934838 T ES 97934838T ES 97934838 T ES97934838 T ES 97934838T ES 2174273 T3 ES2174273 T3 ES 2174273T3
Authority
ES
Spain
Prior art keywords
treatment
prevention
combination
heparan
quitosan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97934838T
Other languages
English (en)
Inventor
Olle Larm
Marcus Back
Tomas Bergstrom
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medicarb AB
Original Assignee
Medicarb AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medicarb AB filed Critical Medicarb AB
Application granted granted Critical
Publication of ES2174273T3 publication Critical patent/ES2174273T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

SE PRESENTA LA UTILIZACION DE HEPARINA O DE SULFATO DE HEPARAN EN COMBINACION CON QUITOSAN PARA LA FABRICACION DE UN MEDICAMENTO PARA LA PREVENCION O EL TRATAMIENTO DE INFECCIONES PROVOCADAS POR EL VIRUS DEL HERPES EN MAMIFEROS, INCLUYENDO EL HOMBRE; ASI COMO UN PROCESO PARA EL TRATAMIENTO DE LAS ENFERMEDADES INFECCIOSAS PROVOCADAS POR LOS VIRUS DEL HERPES.
ES97934838T 1996-08-06 1997-08-01 Uso de heparina o heparan-sulfato en combinacion con quitosan para la prevencion o el tratamiento de infecciones causadas por virus herpes. Expired - Lifetime ES2174273T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9602931A SE507028C2 (sv) 1996-08-06 1996-08-06 Ny medicinsk användning

Publications (1)

Publication Number Publication Date
ES2174273T3 true ES2174273T3 (es) 2002-11-01

Family

ID=20403528

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97934838T Expired - Lifetime ES2174273T3 (es) 1996-08-06 1997-08-01 Uso de heparina o heparan-sulfato en combinacion con quitosan para la prevencion o el tratamiento de infecciones causadas por virus herpes.

Country Status (13)

Country Link
US (1) US6207653B1 (es)
EP (1) EP0930885B1 (es)
JP (1) JP2000515543A (es)
CN (1) CN1227493A (es)
AT (1) ATE215829T1 (es)
AU (1) AU705189B2 (es)
CA (1) CA2261742A1 (es)
DE (1) DE69711897T2 (es)
DK (1) DK0930885T3 (es)
ES (1) ES2174273T3 (es)
NZ (1) NZ333925A (es)
SE (1) SE507028C2 (es)
WO (1) WO1998005341A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE508760C2 (sv) 1997-04-29 1998-11-02 Medicarb Ab Användning av en komposition innefattande kitosan i kombination med en polysackarid, som aktiv komponent i ett lösningsmedel, för framställning av ett spendoppningsmedel för mjölkproducerande djur
AU7070700A (en) * 1999-08-25 2001-03-19 Massachusetts Institute Of Technology Pharmaceutical preparations for the inhibition of herpes simplex virus 1 entry
US6977248B1 (en) * 1999-08-25 2005-12-20 Massachusetts Institute Of Technology Pharmaceutical preparations for the inhibition of herpes simplex virus 1 entry
US20020119949A1 (en) * 2001-02-26 2002-08-29 Asa Hellman Prophylactic teat treatment
US7968122B2 (en) * 2003-12-10 2011-06-28 Adventrx Pharmaceuticals, Inc. Anti-viral pharmaceutical compositions
EP1774971A1 (en) * 2005-10-14 2007-04-18 Advanced in Vitro Cell Technologies, S.L. Chitosan and heparin nanoparticles
ES2608399T3 (es) * 2005-12-13 2017-04-10 Exthera Medical Corporation Método para la eliminación extracorpórea de un microbio patógeno, una célula inflamatoria o una proteína inflamatoria de la sangre
WO2008155683A1 (en) 2007-06-18 2008-12-24 Firmenich Sa Malodor counteracting compositions and method for their use
CL2008000156A1 (es) * 2008-01-18 2008-08-01 Igloo Zone Chile S A Gel estable hidrofilo en base a un polimero para aplicacion topica porque comprende quitosano disuelto en un solvente; proceso para obtener el gel para uso topico antes mencionado; uso del gel.
US8906883B2 (en) * 2009-06-10 2014-12-09 Exthera Ab Treatment of oral mucositis by administering an ionic complex of chitosan and a negatively charged polysaccharide selected from heparin, heparan sulfate and dextran sulfate
ES2861359T3 (es) 2009-12-01 2021-10-06 Exthera Medical Corp Dispositivo para eliminar citoquinas de la sangre con polisacáridos inmovilizados en superficie
US20110212181A1 (en) * 2010-02-26 2011-09-01 The University Of Hong Kong Compositions and methods for treating chronic respiratory inflammation
NO2557151T3 (es) * 2010-04-07 2018-03-03
JPWO2011142484A1 (ja) * 2010-05-14 2013-07-22 株式会社日本触媒 ポリアルキレンイミンを含むウイルス感染症治療薬
WO2012112724A1 (en) 2011-02-15 2012-08-23 Exthera Medical, Llc Device and method for removal of blood-borne pathogens, toxins and inflammatory cytokines
WO2013188073A1 (en) 2012-06-13 2013-12-19 Exthera Medical, Llc Use of heparin and carbohydrates to treat cancer
WO2014209782A1 (en) 2013-06-24 2014-12-31 Exthera Medical Corporation Blood filtration system containing mannose coated substrate
AU2014346668C1 (en) 2013-11-08 2018-04-26 Exthera Medical Corporation Methods for diagnosing infectious diseases using adsorption media
AU2015250107A1 (en) 2014-04-24 2016-11-17 Exthera Medical Corporation Method for removing bacteria from blood using high flow rate
AU2015321601B2 (en) 2014-09-22 2020-04-23 Exthera Medical Corporation Wearable hemoperfusion device
US11911551B2 (en) 2016-03-02 2024-02-27 Exthera Medical Corporation Method for treating drug intoxication
US10786615B2 (en) 2016-03-02 2020-09-29 Exthera Medical Corporation Method for treating drug intoxication
EP4228595A1 (en) * 2020-10-14 2023-08-23 Medoderm GmbH Liquid composition for use in the prevention or reduction of skin irritation, allergy and/or an infectious disease
WO2023044132A2 (en) * 2021-09-17 2023-03-23 Shawn Walker Use of chitosan complexes or compositions to reduce infiltration of environmental factors into the brain

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU77562A1 (de) 1977-06-17 1979-03-26 Ciba Geigy Ag Verfahren zur herstellung von neuen pharmazeutischen praeparaten
EP0240098A3 (en) * 1986-04-04 1989-05-10 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Oligo and polysaccharides for the treatment of diseases caused by retroviruses
AU1052492A (en) 1991-01-31 1992-08-06 Farmitalia Carlo Erba S.R.L. Synergistic composition comprising a fibroblast growth factor and a sulfated polylsaccharide, for use as antiviral agent

Also Published As

Publication number Publication date
CN1227493A (zh) 1999-09-01
CA2261742A1 (en) 1998-02-12
ATE215829T1 (de) 2002-04-15
SE9602931D0 (sv) 1996-08-06
DE69711897D1 (de) 2002-05-16
SE9602931L (sv) 1998-02-07
DE69711897T2 (de) 2002-08-22
AU705189B2 (en) 1999-05-20
WO1998005341A1 (en) 1998-02-12
EP0930885A1 (en) 1999-07-28
EP0930885B1 (en) 2002-04-10
DK0930885T3 (da) 2002-05-06
US6207653B1 (en) 2001-03-27
AU3791197A (en) 1998-02-25
NZ333925A (en) 2000-07-28
SE507028C2 (sv) 1998-03-16
JP2000515543A (ja) 2000-11-21

Similar Documents

Publication Publication Date Title
ES2174273T3 (es) Uso de heparina o heparan-sulfato en combinacion con quitosan para la prevencion o el tratamiento de infecciones causadas por virus herpes.
BR9606769A (pt) Tablete e processos para tratamento de uma infecção de vírus do herpes em um humano e para preparação do tablete
BR9913935A (pt) Métodos de tratamento e prevenção de infecção causada por pelo menos um vìrus da famìlia dos flaviviridae e doença associada com a dita infecção em um hospedeiro vivo
BR9913406A (pt) Processo de tratamento de infecção causada por pelo menos um vìrus da famìlia flaviviridae e de doença associada com a citada infecção em um hospedeiro vivo possuindo a citada infecção
BR9811121A (pt) Produto, composição farmacêutica, e uso de um produto
HUP9902055A3 (en) Medical composition for the treatment of herpes simplex virus and other infectious diseases
BR0111195A (pt) Uso de b-l-2'-desoxi-nucleosìdeos no tratamento de infecção por vìrus de hepatite delta
BR9408585A (pt) Artigo tendo porção de cintura frontal porção de cintura posterior e porção intermediária interligando as porções de cintura frontal e posterior e artigo de fixação
CA2194976A1 (en) Wound healing agent
ES2058892T3 (es) Uso de omeprazol como agente antimicrobiano.
CA2293470A1 (en) Benzimidazole derivatives
BR0112962A (pt) Composições farmacêuticas para o tratamento de condições inflamatórias e ulcerativas dolorosas de maioria das superfìcies epiteliais tais como mucosite, estomatite e sìndrome de behcet
ITTO940713A0 (it) Vaccino per la prevenzione della sindrome riproduttiva e respiratoria porcina.
PT98565A (pt) Um processo de producao de uma composicao para o tratamento da infeccao por hsv
DK0772446T3 (da) Anti-adhæsionsmiddel
ATE66133T1 (de) Kondom.
EP0333243A3 (en) Sulphated k5 antigen and sulphated k5 antigen fragments
ES2053953T3 (es) Uso de fracciones de heparina o fragmentos de heparina.
BR9306207A (pt) Composiçao farmacéutica e processo para o tratamento de infecçao ou doença causada pelo vírus da hepatite b processo para a preparaçao da composiçao e uso de fiau ou de uma pró-droga ou metabolito do mesmo
BR9916043A (pt) Composto, uso do mesmo e de seus saisfarmaceuticamente aceitáveis, e, composiçãofarmacêutica para tratamento de infecções deherpes viral em pacientes
BR9706938A (pt) Composto uso do mesmo formulação farmacêutica e processos para produzir o composto e para o tratamento ou a prevenção de sintomas ou efeitos de uma infecção virótica em um mamífero infectado incluindo um humano
GB8926595D0 (en) Pharmaceutical compositions for use in the treatment herpes simplex virus infections
AU2880595A (en) Use of pharmaceutical agents for restoring, alleviation, or treatment of immunodeficiency, including the alleviation or treatment of the immune dysfunction related to infection with human immunodeficiency viruses (hiv) or related viruses
ES2162862T3 (es) Uso de la timosina para tratar la hepatitis c en pacientes que no responden al tratamiento con interferon.
ATE91419T1 (de) Synergistische kombination zur ophthalmischen verwendung.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 930885

Country of ref document: ES